Eikonoklastes Therapeutics

1 follower


Eikonoklastes is advancing a new generation of tissue factor (TF) immunotherapies – therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment.

Employees

1-10

Links


Org chart

Bruce Halpryn
Co-Founder & CEO
Collapse
Samuel Lee
Co-Founder & Chief Business Officer
Samuel Lee, MD, MBA
Co-Founder, President, and Chief Business Officer
Brian Head
Inventor
Zhiwei Hu
Inventor

Board & advisors

Neel Patel
Director
Meyer Frucher
Board Member
Tom Finn
Director
Seward Rutkove
Scientific Advisor
Russell Lonser
Scientific Advisor
Dame Pamela Shaw
Scientific Advisor
Mark Tuszynski
Scientific Advisor
Michael O’Beirne
Scientific Advisor